Thursday, January 9, 2014
Publication and contact
Mouse studies suggest
antagonizing IL-12 or using vaccines that limit IL-12 production could help
protect against influenza infection. In mice primed with dendritic cells
presenting an influenza A virus nucleoprotein
(NP) epitope (DC-NP), those
boosted with an NP-expressing vaccinia virus had lower levels of IL-12 and
higher numbers of respiratory, NP-specific memory CD8+ T cells than those boosted with NP-expressing Listeria
monocytogenes (LM-NP). In a mouse model of influenza A virus infection,
adding an anti-IL-12 antibody to the prime and LM-NP boost regimen increased
the number of memory CD8+ T cells and
decreased viral titer compared with adding IgG. Next steps could include
finding additional cytokines that affect the formation of memory CD8+ T cells.
Bristol-Myers Squibb Co.
and Johnson & Johnson
market Stelara ustekinumab, a
human mAb inhibiting IL-12 and IL-23, to treat psoriatic
arthritis and have the drug in Phase III or earlier testing for other
Published online Jan. 9, 2014
Patent and licensing status
Slütter, B. et al.
Immunity; published online Nov. 14, 2013;
Contact: John T. Harty, University of Iowa Carver College of
Iowa City, Iowa
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]